Biotalys Announces Intention to Strategically Refocus its Activities to Prioritize Lead Assets and Reduce Annual Cash Burn
17 February 2026, Belgium: Biotalys (Euronext: BTLS), an Agricultural Technology (AgTech) company developing protein-based biocontrols for sustainable crop protection, today announced its intention to proceed with a strategic refocus designed to concentrate resources on its highest-priority programs and streamline operations accordingly.
As part of this initiative, Biotalys intends to right-size its organizational structure and suspend its early-stage activities to reduce operating expenses, while safeguarding the long-term value of its technology platform. The company intends to prioritize the development and regulatory advancement of its lead biofungicide assets and focus commercial preparation efforts on markets with the highest near-term potential. The intended initiative is expected to result in an estimated reduction in total cash burn until the end of 2028 of €20m versus the current operating structure.
“It is imperative that we deploy capital where it creates the greatest impact,” said Kevin Helash, CEO of Biotalys. “A narrowing of the focus to our core assets and most advanced programs aims to strengthen our ability to deliver innovative, sustainable crop protection solutions to growers and, subject to securing additional funding, to advance our path to long-term value creation.”
The intended strategic transition will focus resources on progressing Biotalys’ most advanced biofungicide programs – EVOCA NG and BioFun-6 – while continuing to support the partnered BioFun-7 program with the Gates Foundation as well as BioIns-2, the company’s insecticide program in partnership with Syngenta. Biotalys will continue process development to achieve commercially competitive manufacturing costs, supported by its recently announced strategic partnership with 21st.BIO. Biotalys will also continue its partnership for the post-harvest market with AgroFresh. This partnership driven approach and intended heightened focus are aimed at de-risking future commercialization efforts.
In this context, Biotalys announced its intention to reduce its workforce by 30 employees to align its cost structure with the intended refocused strategy.1 The company confirms its cash runway into May 2026, as previously announced. Biotalys is in discussion with investors regarding potential financing options, to support the sharpened portfolio. The intended measures should significantly reduce the investment required to deliver on Biotalys’ goal of becoming a pioneer of Precision Biocontrols generating value for its shareholders and stakeholders and growers worldwide.
Also Read: France Becomes First Market to Approve Syngenta’s X-Terra Hybrid Wheat
Global Agriculture is an independent international media platform covering agri-business, policy, technology, and sustainability. For editorial collaborations, thought leadership, and strategic communications, write to pr@global-agriculture.com
